Antitumor Activity of α-Linolenic Acid-Paclitaxel Conjugate Nanoparticles: In vitro and in vivo
Mei-Qi Xu,1,2 Yan-Li Hao,1,2 Jing-Ru Wang,1,2 Zhuo-Yue Li,1,2 Hui Li,1 Zhen-Han Feng,1,2 Hui Wang,1,2 Jing-Wen Wang,1,2 Xuan Zhang1,2 1Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, People’s Repu...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/ebf68f734ce4462882532cab81f1b9e2 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:ebf68f734ce4462882532cab81f1b9e2 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:ebf68f734ce4462882532cab81f1b9e22021-12-02T19:35:47ZAntitumor Activity of α-Linolenic Acid-Paclitaxel Conjugate Nanoparticles: In vitro and in vivo1178-2013https://doaj.org/article/ebf68f734ce4462882532cab81f1b9e22021-10-01T00:00:00Zhttps://www.dovepress.com/antitumor-activity-of--linolenic-acid-paclitaxel-conjugate-nanoparticl-peer-reviewed-fulltext-article-IJNhttps://doaj.org/toc/1178-2013Mei-Qi Xu,1,2 Yan-Li Hao,1,2 Jing-Ru Wang,1,2 Zhuo-Yue Li,1,2 Hui Li,1 Zhen-Han Feng,1,2 Hui Wang,1,2 Jing-Wen Wang,1,2 Xuan Zhang1,2 1Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, People’s Republic of China; 2Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, People’s Republic of ChinaCorrespondence: Xuan ZhangDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Xueyuan Road 38, Beijing, 100191, People’s Republic of ChinaTel +86-10-82805765Fax +86-10-8280576Email xuanzhang@bjmu.edu.cnPurpose: Small molecule modified antitumor drug conjugate nanoparticles have the advantages of high drug loading, simple synthesis and preparation, and better biocompatibility. Due to the large demand for exogenous α-linolenic acid (ALA) by tumor cells, we synthesized α-linolenic acid-paclitaxel conjugate (ALA-PTX) and prepared α-linolenic acid-paclitaxel conjugate nanoparticles (ALA-PTX NPs), in order to obtain better tumor cellular uptake and antitumor activity in vitro and in vivo.Methods: We synthesized and characterized ALA-PTX, and then prepared and characterized ALA-PTX NPs. The cellular uptake, uptake pathways, intracellular behavior, in vitro and in vivo antitumor activity of ALA-PTX NPs were evaluated.Results: The size of ALA-PTX NPs was approximately 110.7± 1.7 nm. The drug loading was approximately 90% (w/w) with CrEL-free and organic solvent-free characteristics. The cellular uptake of ALA-PTX NPs was significantly higher than that of PTX injection by MCF-7, MCF-7/ADR and HepG2 cells. In these three cell lines, the cellular uptake of ALA-PTX NPs at 6h was approximately 1.5– 2.6 times higher than that of PTX injection. ALA-PTX NPs were ingested through clathrin-mediated endocytosis, then transferred to lysosomes, and could dissolve in cells to play an antitumor activity. The in vitro and in vivo antitumor activity of ALA-PTX NPs was confirmed in MCF-7/ADR and HepG2 cell models and tumor-bearing nude mouse models.Conclusion: ALA-PTX NPs developed in our study could provide a new method for the preparation of nano-delivery systems suitable for antitumor therapy that could increase tumor cellular uptake and enhance antitumor activity.Keywords: α-linolenic acid, α-linolenic acid-paclitaxel conjugate, α-linolenic acid-paclitaxel conjugate nanoparticles, cellular uptake, antitumor activityXu MQHao YLWang JRLi ZYLi HFeng ZHWang HWang JWZhang XDove Medical Pressarticleα-linolenic acidα-linolenic acid-paclitaxel conjugateα-linolenic acid-paclitaxel conjugate nanoparticlescellular uptakeantitumor activityMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 16, Pp 7269-7281 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
α-linolenic acid α-linolenic acid-paclitaxel conjugate α-linolenic acid-paclitaxel conjugate nanoparticles cellular uptake antitumor activity Medicine (General) R5-920 |
| spellingShingle |
α-linolenic acid α-linolenic acid-paclitaxel conjugate α-linolenic acid-paclitaxel conjugate nanoparticles cellular uptake antitumor activity Medicine (General) R5-920 Xu MQ Hao YL Wang JR Li ZY Li H Feng ZH Wang H Wang JW Zhang X Antitumor Activity of α-Linolenic Acid-Paclitaxel Conjugate Nanoparticles: In vitro and in vivo |
| description |
Mei-Qi Xu,1,2 Yan-Li Hao,1,2 Jing-Ru Wang,1,2 Zhuo-Yue Li,1,2 Hui Li,1 Zhen-Han Feng,1,2 Hui Wang,1,2 Jing-Wen Wang,1,2 Xuan Zhang1,2 1Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, People’s Republic of China; 2Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, People’s Republic of ChinaCorrespondence: Xuan ZhangDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Xueyuan Road 38, Beijing, 100191, People’s Republic of ChinaTel +86-10-82805765Fax +86-10-8280576Email xuanzhang@bjmu.edu.cnPurpose: Small molecule modified antitumor drug conjugate nanoparticles have the advantages of high drug loading, simple synthesis and preparation, and better biocompatibility. Due to the large demand for exogenous α-linolenic acid (ALA) by tumor cells, we synthesized α-linolenic acid-paclitaxel conjugate (ALA-PTX) and prepared α-linolenic acid-paclitaxel conjugate nanoparticles (ALA-PTX NPs), in order to obtain better tumor cellular uptake and antitumor activity in vitro and in vivo.Methods: We synthesized and characterized ALA-PTX, and then prepared and characterized ALA-PTX NPs. The cellular uptake, uptake pathways, intracellular behavior, in vitro and in vivo antitumor activity of ALA-PTX NPs were evaluated.Results: The size of ALA-PTX NPs was approximately 110.7± 1.7 nm. The drug loading was approximately 90% (w/w) with CrEL-free and organic solvent-free characteristics. The cellular uptake of ALA-PTX NPs was significantly higher than that of PTX injection by MCF-7, MCF-7/ADR and HepG2 cells. In these three cell lines, the cellular uptake of ALA-PTX NPs at 6h was approximately 1.5– 2.6 times higher than that of PTX injection. ALA-PTX NPs were ingested through clathrin-mediated endocytosis, then transferred to lysosomes, and could dissolve in cells to play an antitumor activity. The in vitro and in vivo antitumor activity of ALA-PTX NPs was confirmed in MCF-7/ADR and HepG2 cell models and tumor-bearing nude mouse models.Conclusion: ALA-PTX NPs developed in our study could provide a new method for the preparation of nano-delivery systems suitable for antitumor therapy that could increase tumor cellular uptake and enhance antitumor activity.Keywords: α-linolenic acid, α-linolenic acid-paclitaxel conjugate, α-linolenic acid-paclitaxel conjugate nanoparticles, cellular uptake, antitumor activity |
| format |
article |
| author |
Xu MQ Hao YL Wang JR Li ZY Li H Feng ZH Wang H Wang JW Zhang X |
| author_facet |
Xu MQ Hao YL Wang JR Li ZY Li H Feng ZH Wang H Wang JW Zhang X |
| author_sort |
Xu MQ |
| title |
Antitumor Activity of α-Linolenic Acid-Paclitaxel Conjugate Nanoparticles: In vitro and in vivo |
| title_short |
Antitumor Activity of α-Linolenic Acid-Paclitaxel Conjugate Nanoparticles: In vitro and in vivo |
| title_full |
Antitumor Activity of α-Linolenic Acid-Paclitaxel Conjugate Nanoparticles: In vitro and in vivo |
| title_fullStr |
Antitumor Activity of α-Linolenic Acid-Paclitaxel Conjugate Nanoparticles: In vitro and in vivo |
| title_full_unstemmed |
Antitumor Activity of α-Linolenic Acid-Paclitaxel Conjugate Nanoparticles: In vitro and in vivo |
| title_sort |
antitumor activity of α-linolenic acid-paclitaxel conjugate nanoparticles: in vitro and in vivo |
| publisher |
Dove Medical Press |
| publishDate |
2021 |
| url |
https://doaj.org/article/ebf68f734ce4462882532cab81f1b9e2 |
| work_keys_str_mv |
AT xumq antitumoractivityofalphalinolenicacidpaclitaxelconjugatenanoparticlesinvitroandinvivo AT haoyl antitumoractivityofalphalinolenicacidpaclitaxelconjugatenanoparticlesinvitroandinvivo AT wangjr antitumoractivityofalphalinolenicacidpaclitaxelconjugatenanoparticlesinvitroandinvivo AT lizy antitumoractivityofalphalinolenicacidpaclitaxelconjugatenanoparticlesinvitroandinvivo AT lih antitumoractivityofalphalinolenicacidpaclitaxelconjugatenanoparticlesinvitroandinvivo AT fengzh antitumoractivityofalphalinolenicacidpaclitaxelconjugatenanoparticlesinvitroandinvivo AT wangh antitumoractivityofalphalinolenicacidpaclitaxelconjugatenanoparticlesinvitroandinvivo AT wangjw antitumoractivityofalphalinolenicacidpaclitaxelconjugatenanoparticlesinvitroandinvivo AT zhangx antitumoractivityofalphalinolenicacidpaclitaxelconjugatenanoparticlesinvitroandinvivo |
| _version_ |
1718376412733243392 |